Table 2.
Demographics, medical characteristics, and key study variables of the participants (N = 78).
| Variable | Mean (SD) | Range | |
|---|---|---|---|
| Sociodemographics | |||
|
| |||
| Age after surgery (years) | 49.55 (7.51) | 32.00 – 69.00 | |
|
| |||
| Years of Education | 15.86 (2.58) | 8.00 – 23.00 | |
|
| |||
| Employment | Employed full time | 64 (82.1%) | – |
| Not employed full time | 14 (17.9%) | – | |
|
| |||
| Income (thousands of US dollars) | 76.19 (49.20) | 15.00 – 300.00 | |
|
| |||
| Ethnic Identification | Non-Hispanic White | 54 (69.2%) | – |
| Hispanic/Latino | 16 (20.5%) | – | |
| African American/Black | 7 (9.0%) | – | |
| Other | 1 (1.3%) | – | |
|
| |||
| Marital Status | Married/Partnered | 53 (67.9%) | – |
| Separated | 2 (2.6%) | – | |
| Divorced | 19 (24.4%) | – | |
| Single | 4 (5.1%) | – | |
|
| |||
| Children | Yes | 24 (30.8%) | – |
| No | 54 (69.2%) | – | |
|
| |||
| Number of Children | 2.11 (0.85) | 1.00 – 5.00 | |
|
| |||
| Medical Status | |||
|
| |||
| Cancer Stagea | Stage 0 | 10 (12.8%) | – |
| Stage I | 37 (47.4%) | – | |
| Stage II | 24 (30.8%) | – | |
| Stage III | 7 (9.0%) | – | |
|
| |||
| Surgery | Lumpectomy | 34 (43.6%) | – |
| Mastectomy | 44 (56.4%) | – | |
|
| |||
| Days since Surgery | 38.58 (24.22) | 10.00 – 133.00 | |
|
| |||
| Estrogen Receptor Status | Positive | 43 (55.1%) | – |
| Negative | 8 (10.3%) | – | |
| Unknown | 27 (34.6%) | – | |
|
| |||
| Progesterone Receptor Status | Positive | 28 (35.9%) | – |
| Negative | 11 (14.1%) | – | |
| Unknown | 39 (50.0%) | – | |
|
| |||
| HER2/neu Status | Positive | 11 (14.1%) | – |
| Negative | 31 (39.7%) | – | |
| Unknown | 36 (46.2%) | – | |
|
| |||
| Medication Use | Anti-depressant | 5 (6.4%) | – |
| Anti-anxiety | 13 (16.7%) | – | |
| Sleep | 12 (15.4%) | – | |
| Pain | 22 (28.2%) | – | |
|
| |||
| Body Mass Index (kg/m2) | 26.96 (6.49) | 18.88 – 55.81 | |
|
| |||
| Gene Expression | |||
|
| |||
| Cytokine Composite | 10.67 (1.21) | 8.73 – 13.23 | |
|
| |||
| Chemokine Composite | 10.87 (1.29) | 7.84 – 13.04 | |
|
| |||
| Pro-Metastatic Composite | 9.58 (0.86) | 7.52 – 11.36 | |
|
| |||
| IL1A | 9.39 (1.83) | 6.77 – 12.75 | |
|
| |||
| IL1B | 13.05 (1.52) | 8.08 – 14.55 | |
|
| |||
| IL6 | 10.36 (2.03) | 7.26 – 14.95 | |
|
| |||
| TNFSF10 | 9.54 (1.15) | 6.87 – 13.17 | |
|
| |||
| TNFRSF21 | 10.25 (0.90) | 7.75 – 12.38 | |
|
| |||
| CCL3 | 12.83 (1.55) | 8.43 – 15.06 | |
|
| |||
| CCL7 | 10.22 (1.54) | 6.88 – 13.61 | |
|
| |||
| CCL20 | 10.58 (2.02) | 7.40 – 14.00 | |
|
| |||
| CCL3L1 | 12.11 (1.60) | 7.78 – 14.75 | |
|
| |||
| CCL4L2 | 11.35 (1.51) | 8.60 – 13.92 | |
|
| |||
| CXCR7 | 8.09 (0.78) | 7.09 – 10.61 | |
|
| |||
| PTGS2 | 11.45 (1.32) | 9.00 – 13.65 | |
|
| |||
| MMP9 | 9.20 (1.04) | 7.15 – 11.53 | |
|
| |||
| LMNA | 9.96 (0.84) | 7.89 – 11.85 | |
|
| |||
| Survey Data | |||
|
| |||
| Social Well-Being | 22.56 (4.71) | 8.17 – 28.00 | |
| Emotional Well-Being | 17.77 (4.12) | 4.00 – 24.00 | |
| Physical Well-Being | 20.90 (5.21) | 3.00 – 28.00 | |
| Functional Well-Being | 18.75 (5.73) | 2.00 – 28.00 | |
|
| |||
| Hamilton Depression Score | 6.68 (5.52) | 0.00 – 23.00 | |
a
TNM staging system.
b
SD = Standard deviation; HP = husband/partner; AW = adult women; CMAF = children and male adult family; FR = friends. Gene expression reported in RNA expression units (log2).